Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-07-03 6:39 pm Purchase | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 52,131,254 75.04% | 21,855,950 (+72.19%) | View |
| 2023-07-03 4:01 pm Unchanged | 13G | Navidea Biopharmaceuticals, Inc. NAVB | Bain Irwin Allen | 4,000,000 4.73% | 0 (Unchanged) | View |
| 2023-06-30 4:01 pm Purchase | 13G | Navidea Biopharmaceuticals, Inc. NAVB | Bain Irwin Allen | 4,000,000 4.73% | 2,053,383 (+105.48%) | View |
| 2023-06-16 4:20 pm Purchase | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 30,275,304 52.85% | 11,508,672 (+61.33%) | View |
| 2022-10-06 2:51 pm Purchase | 13G | Navidea Biopharmaceuticals, Inc. NAVB | Bain Irwin Allen | 1,946,617 6.23% | 1,946,617 (New Position) | View |
| 2022-09-22 3:03 pm Sale | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 18,766,632 45.7% | -533 (-0.00%) | View |
| 2022-09-14 3:25 pm Sale | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 18,767,165 45.7% | -10,139 (-0.05%) | View |
| 2022-09-09 5:59 pm Purchase | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 18,777,304 45.7% | 8,491,133 (+82.55%) | View |
| 2022-04-22 2:58 pm Purchase | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 10,286,171 31.6% | 54,957 (+0.54%) | View |
| 2021-07-23 4:27 pm Unchanged | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 10,231,214 32.8% | 0 (Unchanged) | View |
| 2021-06-15 11:46 am Unchanged | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 10,231,214 32.8% | 0 (Unchanged) | View |
| 2021-04-05 5:00 pm Purchase | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 10,231,214 33.3% | 267,530 (+2.69%) | View |
| 2021-03-11 5:07 pm Unchanged | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 9,963,684 33.33% | 0 (Unchanged) | View |
| 2021-03-05 5:24 pm Purchase | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 9,963,684 33.33% | 1,906,383 (+23.66%) | View |
| 2020-12-29 4:15 pm Unchanged | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 8,057,301 30.2% | 0 (Unchanged) | View |
| 2020-09-02 5:18 pm Purchase | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 8,057,301 30% | 5,000 (+0.06%) | View |
| 2020-02-26 4:35 pm Purchase | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 8,052,301 33.2% | 2,373,529 (+41.80%) | View |
| 2019-12-12 4:32 pm Purchase | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 5,678,772 28.2% | 555,555 (+10.84%) | View |
| 2019-06-24 5:15 pm Sale | 13D | Navidea Biopharmaceuticals, Inc. NAVB | Scott John K Jr. | 5,123,217 28.4% | -16,983,990 (-76.83%) | View |
| 2019-06-24 4:36 pm Unchanged | 13G | Navidea Biopharmaceuticals, Inc. NAVB | ARMISTICE CAPITAL LLC | 0 0% | 0 (Unchanged) | View |